Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+60.0%
5Y CAGR+42.3%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+60.0%/yr
vs +64.2%/yr prior
5Y CAGR
+42.3%/yr
Recent acceleration
Acceleration
-4.2pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.8x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$1.20B+79.0%
2024$671.77M+76.6%
2023$380.50M+29.6%
2022$293.57M+21.1%
2021$242.48M+17.8%
2020$205.85M+117.0%
2019$94.86M+135.0%
2018$40.36M+26.9%
2017$31.81M+27.3%
2016$24.98M-